UBS Downgrades Crinetics Pharmaceuticals to Neutral, Raises Price Target to $85

Benzinga · 3d ago
UBS analyst Ashwani Verma downgrades Crinetics Pharmaceuticals (NASDAQ:CRNX) from Buy to Neutral and raises the price target from $55 to $85.